Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP3882)
Name
L-canavanine
Synonyms
canavanine; L-canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-((Aminoiminomethyl)amino)homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; GGB; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; C5H12N4O3; HSDB 3471; L(+)-Canavanine; Spectrum_001137; Tocris-0673; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Prestwick3_000609; Spectrum2_000800; Spectrum3_001206; Spectrum4_000783; Spectrum5_001884; Lopac-C-9758; bmse000073; Lopac0_000320; BSPBio_000518; BSPBio_002592; KBioGR_001226; KBioSS_001617; DivK1c_000360; O-carbamimidamido-L-homoserine; SCHEMBL151097; SPECTRUM1500833; SPBio_000940; BPBio1_000570; DTXSID5045041; HMS501B22; KBio1_000360; KBio2_001617; KBio2_004185; KBio2_006753; KBio3_002092; NINDS_000360; HMS1921K08; ZINC3869452; BDBM50271982; BDBM50370459; CCG-40178; AKOS006240676; DB01833; SDCCGMLS-0066683.P001; SDCCGSBI-0050308.P003; IDI1_000360; SMP1_000062; NCGC00015287-01; NCGC00015287-18; NCGC00015287-19; NCGC00024722-01; NCGC00024722-02; NCGC00024722-03; NCGC00024722-04; (2S)-2-amino-4-guanidinooxy-butanoic acid; (S)-2-Amino-4-(guanidinooxy)butanoic acid; O-{[Amino(imino)methyl]amino}-L-homoserine; X6876; Butyric acid, 2-amino-4-(guanidinooxy)-, L; C00308; (2S)-2-amino-4-(carbamimidamidooxy)butanoic acid; L-Alpha-amino-gamma-[guanidinooxy]-N-butyric acid; Q418408; L-Homoserine, O-((aminoiminomethyl)amino)- (9CI); [Eur.J.Pharmacol. 269:269; 271:87 (1994)]; UNII-QXB6XSA047 component FSBIGDSBMBYOPN-VKHMYHEASA-N; (2s)-2-amino-4-(((diaminomethylidene)amino)oxy)butanoic acid; 56C22C33-8657-4884-BE16-CAF24BF61D77; L-Canavanine, >=98% (TLC), powder, from Canavalia ensiformis
    Click to Show/Hide
Species Origin Canavalia ensiformis ...     Click to Show/Hide
Canavalia ensiformis
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Canavalia
Species: Canavalia ensiformis
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C5H12N4O3
PubChem CID
439202
Canonical SMILES
C(CON=C(N)N)C(C(=O)O)N
InChI
1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1
InChIKey
FSBIGDSBMBYOPN-VKHMYHEASA-N
CAS Number
CAS 543-38-4
ChEBI ID
CHEBI:609827
Herb ID
HBIN019533
SymMap ID
SMIT14563
TTD Drug ID
D0V9FZ
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          5-fluorouracil      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MIA PaCa-2 CVCL_0428 Pancreatic ductal adenocarcinoma Homo sapiens
                    In-vivo Model Male Fishcher rats weighing 150-175 g were used in this study.
                    Experimental
                    Result(s)
Combination therapy offers a viable means of improving L-canavanine's intrinsic efficacy while decreasing the concentration of 5-FU required to produce the same cytotoxic effect.
Target and Pathway
Target(s) Nitric-oxide synthase endothelial (NOS3)  Molecule Info  [3]
BioCyc Citrulline-nitric oxide cycle Click to Show/Hide
KEGG Pathway Arginine and proline metabolism Click to Show/Hide
2 Metabolic pathways
3 Calcium signaling pathway
4 cGMP-PKG signaling pathway
5 HIF-1 signaling pathway
6 Sphingolipid signaling pathway
7 PI3K-Akt signaling pathway
8 VEGF signaling pathway
9 Platelet activation
10 Estrogen signaling pathway
11 Oxytocin signaling pathway
NetPath Pathway Wnt Signaling Pathway Click to Show/Hide
Panther Pathway Angiogenesis Click to Show/Hide
2 Endothelin signaling pathway
3 Interleukin signaling pathway
4 PI3 kinase pathway
5 VEGF signaling pathway
Pathway Interaction Database Plasma membrane estrogen receptor signaling Click to Show/Hide
2 Validated transcriptional targets of AP1 family members Fra1 and Fra2
3 Angiopoietin receptor Tie2-mediated signaling
4 Thromboxane A2 receptor signaling
5 SHP2 signaling
6 VEGFR1 specific signals
7 Signaling events mediated by VEGFR1 and VEGFR2
8 PAR1-mediated thrombin signaling events
Reactome ROS production in response to bacteria Click to Show/Hide
2 Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
3 eNOS activation
4 Nitric oxide stimulates guanylate cyclase
5 VEGFR2 mediated vascular permeability
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
2 EGF/EGFR Signaling Pathway
3 Myometrial Relaxation and Contraction Pathways
4 JAK/STAT
5 Corticotropin-releasing hormone
6 AGE/RAGE pathway
7 Endothelin Pathways
8 Leptin signaling pathway
9 Effects of Nitric Oxide
10 Metabolism of nitric oxide
11 Angiogenesis
References
Reference 1 Arginine antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xL. Biochem Biophys Res Commun. 2002 Jul 12;295(2):283-8.
Reference 2 Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. Anticancer Drugs. 1995 Aug;6(4):586-93.
Reference 3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China